18H0 Stock Chart & Stats
€0.02
<€0.01(40.00%)
At close: 4:00 PM EDT
€0.02
<€0.01(40.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume10.00K
Average Volume (3M)8.48K
Market Cap
€9.94M
Enterprise Value€13.85
Total Cash (Recent Filing)€35.66K
Total Debt (Recent Filing)€4.84M
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding638,186,950
10 Day Avg. Volume1,450
30 Day Avg. Volume8,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug-delivery And Therapeutic R&D PlatformA focused portfolio spanning therapeutic formulations and delivery technologies provides multiple routes to future commercialization, licensing, or partnering. If development milestones are achieved, this platform could create intellectual-property value beyond any single product candidate over the next several quarters.
Improved Asset BaseAsset growth versus prior years is a modest sign that the company has expanded its resource base rather than contracted continuously. While this does not offset the equity deficit or leverage, a larger asset base can support continued research activity and potential commercialization efforts.
Cash Burn Broadly Reflects Accounting LossesThe close relationship between reported losses and cash outflows suggests the company’s weak cash generation is visible in its operating results rather than being driven primarily by unusual working-capital movements. That alignment improves interpretability of performance, even though absolute cash burn remains negative.
Bears Say
No Demonstrated Revenue BaseZero reported revenue across periods shows that the business has not yet demonstrated commercial traction from its product candidates or intellectual property. Without an operating revenue base, near-term progress remains dependent on development success, commercialization, licensing, or external financing.
Negative Equity And High LeverageThe persistent equity deficit and debt that substantially exceeds the asset base indicate a weak capital structure and limited financial flexibility. This can constrain investment in research and commercialization while increasing dependence on refinancing, new capital, or other funding actions.
Persistent And Worsening Cash BurnNegative operating and free cash flow across all periods indicates that the company is not currently self-funding its activities. The latest deterioration suggests funding needs may be rising, which could divert resources from development and increase reliance on financing or dilution.
PreveCeutical Medical News
18H0 FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is €9.94M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Nov 19, 2026 which is in 72 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
PreveCeutical Medical Inc released its earnings results on Aug 28, 2026. The company reported -€0.001 earnings per share for the quarter.
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 638,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
PreveCeutical Medical Inc reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in DE:18H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―